Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis.

PubWeight™: 1.62‹?› | Rank: Top 4%

🔗 View Article (PMID 16729282)

Published in Arthritis Rheum on June 01, 2006

Authors

Elli Kruithof1, Leen De Rycke, Bernard Vandooren, Filip De Keyser, Oliver FitzGerald, Iain McInnes, Paul P Tak, Barry Bresnihan, Eric M Veys, Dominique Baeten, OMERACT Special Interest Group on Synovial Analysis in Clinical Trials

Author Affiliations

1: Ghent University Hospital, Ghent, Belgium.

Articles citing this

Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol (2011) 1.45

Macrophages in synovial inflammation. Front Immunol (2011) 1.13

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis (2008) 0.95

A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A. Am J Pathol (2010) 0.92

Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol (2008) 0.89

Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis (2006) 0.87

Utility of synovial biopsy. Arthritis Res Ther (2009) 0.86

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther (2014) 0.84

Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep (2011) 0.80

Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One (2010) 0.80

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis. Open Rheumatol J (2011) 0.79

Expression profiling in spondyloarthropathy synovial biopsies highlights changes in expression of inflammatory genes in conjunction with tissue remodelling genes. BMC Musculoskelet Disord (2013) 0.77

Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol (2016) 0.77

Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study. Arthritis Res Ther (2011) 0.77

Myeloid-related protein activity in rheumatoid arthritis. Int J Inflam (2011) 0.76

Infliximab in the treatment of ankylosing spondylitis. Biologics (2007) 0.76

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis. J Transl Med (2016) 0.75

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open (2017) 0.75

Biomarkers in spondylarthritis: a peripheral vision. Arthritis Rheum (2006) 0.75

Calprotectin in rheumatic diseases. Exp Biol Med (Maywood) (2016) 0.75

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther (2016) 0.75

Articles by these authors

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12

Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90

Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25

Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75

Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med (2014) 2.54

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis (2012) 2.54

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49

Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum (2011) 2.41

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.35

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum (2002) 2.35

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum (2012) 2.31

Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum (2011) 2.25

Spondyloarthritis. Lancet (2011) 2.25

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17

The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum (2004) 2.12

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis (2013) 2.08

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) (2010) 2.06

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06

Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology (2013) 2.02

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96

Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol (2005) 1.96

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93

Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92

Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87

Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol (2007) 1.87

Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum (2009) 1.87

Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum (2008) 1.86

Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum (2008) 1.84

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis (2007) 1.83

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78

Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum (2010) 1.77

Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med (2013) 1.75

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum (2009) 1.75

Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Ann Rheum Dis (2013) 1.74

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum (2004) 1.73

Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69

Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum (2008) 1.67

Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum (2002) 1.67

Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum (2009) 1.67

Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63

The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum (2008) 1.63

Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther (2005) 1.62

A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther (2006) 1.60

Human T-cell memory consists mainly of unexpanded clones. Immunol Lett (2010) 1.60

The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum (2009) 1.59

Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum (2010) 1.58

The resolution of inflammation. Nat Rev Immunol (2012) 1.58

Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice. Am J Respir Crit Care Med (2011) 1.54

Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis (2011) 1.54

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis (2010) 1.53

Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem (2004) 1.53

Citrullination of epithelial neutrophil-activating peptide 78/CXCL5 results in conversion from a non-monocyte-recruiting chemokine to a monocyte-recruiting chemokine. Arthritis Rheumatol (2014) 1.53

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52

Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum (2007) 1.52

Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52

Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis (2012) 1.51

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.50

B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol (2008) 1.49

Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum (2005) 1.49

The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis (2012) 1.49

MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum (2009) 1.47

Meniscal allograft transplantation: long-term clinical results with radiological and magnetic resonance imaging correlations. Knee Surg Sports Traumatol Arthrosc (2006) 1.46

Zebrafish development and regeneration: new tools for biomedical research. Int J Dev Biol (2009) 1.46

Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum (2011) 1.46

Decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation in patients with juvenile idiopathic arthritis. Arthritis Rheum (2002) 1.45